Penumbra (PEN) Capital Expenditures Growth (3y) (2017 - 2026)
Penumbra (PEN) Capital Expenditures Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | -0.66% |
| 2 | Stryker | 126.77 Bn | 123.30 Bn | 4.50 Bn | 9.94% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 73.18 Bn | 72.64 Bn | 3.85 Bn | 10.89% |
| 5 | Edwards Lifesciences | 52.05 Bn | 47.80 Bn | 1.35 Bn | 11.78% |
| 6 | Dexcom | 34.35 Bn | 32.40 Bn | 830.00 Mn | 12.81% |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 12.62% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | 19.51% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 9.52% |
| 10 | Penumbra | 12.78 Bn | 12.12 Bn | 264.94 Mn | 46.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.10% |
| Mar 31, 2026 | 87.71% |
| Dec 31, 2025 | 31.59% |
| Sep 30, 2025 | -85.00% |
| Jun 30, 2025 | 83.37% |
| Mar 31, 2025 | -29.63% |
| Dec 31, 2024 | -30.99% |
| Sep 30, 2024 | 27.94% |
| Jun 30, 2024 | 66.12% |
| Mar 31, 2024 | 13.43% |
| Dec 31, 2023 | 5.44% |
| Sep 30, 2023 | 76.74% |
| Jun 30, 2023 | -26.96% |
| Mar 31, 2023 | -43.98% |
| Dec 31, 2022 | -748.58% |
| Sep 30, 2022 | 57.86% |
| Jun 30, 2022 | -6.08% |
| Mar 31, 2022 | 79.30% |
| Dec 31, 2021 | 268.21% |
| Sep 30, 2021 | 39.22% |